Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EPS (Weighted Average and Diluted) (2023 - 2025)

Perspective Therapeutics' EPS (Weighted Average and Diluted) history spans 3 years, with the latest figure at $0.01 for Q2 2025.

  • For Q2 2025, EPS (Weighted Average and Diluted) rose 104.07% year-over-year to $0.01; the TTM value through Sep 2025 reached $0.01, up 100.55%, while the annual FY2024 figure was -$1.23, 12.14% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q2 2025 was $0.01 at Perspective Therapeutics, up from -$0.62 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.01 in Q1 2023 and bottomed at -$0.67 in Q4 2023.
  • The 3-year median for EPS (Weighted Average and Diluted) is -$0.25 (2024), against an average of -$0.29.
  • The largest annual shift saw EPS (Weighted Average and Diluted) plummeted 2600.0% in 2024 before it skyrocketed 104.07% in 2025.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.67 in 2023, then grew by 7.46% to -$0.62 in 2024, then skyrocketed by 101.12% to $0.01 in 2025.
  • Per Business Quant, the three most recent readings for CATX's EPS (Weighted Average and Diluted) are $0.01 (Q2 2025), -$0.62 (Q4 2024), and -$0.19 (Q3 2024).